top of page

Okay, you asked, so let's talk GLP-1.



Six years ago, "GLP-1" was a phrase you'd hear in an endocrinology lecture and nowhere else. Now, it's a household term, and I've been asked about GLP-1 more in the last year than pretty much any other supplement or medication. Just in general, acupuncturists do not really have prescriptive power, so while we are generally trained to look at medications for the purpose of herb drug interactions or areas we may wish to flag to a prescribing physician, you'll likely find that acupuncturists generally are in a "stay in my lane" mode when it comes to pharmaceuticals. I will speak to the research and try to give an as accurate as possible lens for how acupuncture, herbs, and/or nutrition stack up as therapeutic approaches for the same aim, but any pharmaceutical decision should be between you and your prescribing provider.


GLP-1, Ozempic, and Peptides: What is the difference?

GLP-1 is a hormone your gut releases naturally after you eat. It slows digestion, tells your pancreas to release insulin, and signals your brain that you're full. Drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are engineered copies of this hormone, built to last about a week in the body instead of the two minutes the natural version survives, which is why they work as a once-weekly injection and why they're so effective for appetite suppression and blood sugar control.


A peptide is a string of amino acids, so it can mean a lot of things. Usually, when someone is saying "Peptide," they are speaking to a broader category that your GLP-1 drugs belong to. Ozempic and Mounjaro are peptides that happen to be extraordinarily well-studied, precisely engineered, and FDA-approved after years of large clinical trials. Most of what else gets marketed under the "peptide" label online, like BPC-157, TB-500, are various growth-hormone-releasing peptides. They share the same basic chemical structure, but unfortunately, the evidence base is not nearly as substantive when the GLP-1 base already has some issues.


The mechanism, briefly

GLP-1 (glucagon-like peptide-1) is released by L-cells in your gut after you eat. It slows gastric emptying, stimulates insulin release, suppresses glucagon, and signals satiety centers in the brainstem and hypothalamus.

  • Semaglutide (Ozempic, Wegovy) mimics this hormone with a longer half-life than the endogenous version.

  • Tirzepatide (Mounjaro, Zepbound) does the same thing plus activates a second gut hormone receptor, GIP.


Here's the part that's tricky. Your body works in cycles and feedback loops to maintain what's called dynamic homeostasis. Often times, there are benefits to every part of the cycle or loop. So if semaglutide and tirzepatide are causing GLP-1 to stay in play for about 5000x its normal half-life, we need to be asking, what is staying on and what is staying off in that time? And when we stay longer in a particular state, what are the downstream results? Time will tell.


The Good

First, cardiovascular and kidney protection, independent of diabetes. The SELECT trial found semaglutide reduced major cardiovascular events by 20% and lowered renal-outcome risk by 22% in people with overweight or obesity and existing cardiovascular disease, without diabetes as an entry criterion. For reference, statins are considered to prevent roughly 25-35% of major vascular events in the primary prevention literature. So as a pharmaceutical for diabetes and weight loss, this is notable.


A follow-up analysis confirmed a slower decline in kidney filtration rate in the semaglutide arm. In people with type 2 diabetes and chronic kidney disease specifically, the FLOW trial showed an 18% reduction in cardiovascular death, heart attack, or stroke, consistent across kidney disease severity. This is pretty substantial, and where folks who are at risk due to weight are concerned, this can really be game changing.


A genuinely interesting reward-pathway story: GLP-1 receptors sit in the same mesolimbic circuitry that governs craving and reward for substances, not just food. Preclinical work in rodents and non-human primates shows GLP-1 receptor agonists blunt dopamine release triggered by alcohol, nicotine, and stimulants, and a 2026 systematic review found this pattern holding up across alcohol, opioid, and psychostimulant models. Human data is thinner and mostly observational so far. A meta-analysis of alcohol-related outcomes found reduced AUDIT scores and lower rates of alcohol-related hospitalization in GLP-1RA users, largely in people already being treated for diabetes or obesity, which makes it hard to fully separate the drug effect from the metabolic-improvement effect. Not saying to go on a GLP-1 drug to quit smoking, but it's interesting.


Okay, the Bad

Muscle, not just fat, comes off, and tirzepatide takes more of it. The SEMALEAN study tracked 106 patients on semaglutide for a year: lean mass dropped 3 kg by month seven before stabilizing, alongside real fat loss and preserved grip strength for most. A 2026 real-world analysis of nearly 8,000 patients found tirzepatide users lost meaningfully more lean body mass relative to total weight loss than semaglutide users at every time point measured, up to 2% more by twelve months and reduced exercise tolerance was the strongest correlate of who lost the most muscle.


This is huge, because once you start hitting yoru 30s and 40s you will already be in a fight to maintain muscle, and a systematic review of tirzepatide trials reaches a similar conclusion. This is where "just eat less and the weight will come off" runs into trouble: on these drugs, without deliberate protein intake and resistance training, a meaningful chunk of what comes off is tissue you want to keep.


Micronutrient status quietly erodes. A 2026 narrative review found over 60% of GLP-1 users consuming below estimated requirements for calcium and iron, vitamin D intake averaging a fifth of recommendations, and thiamine and B12 deficits building over time.


A separate review drawing explicit parallels to post-bariatric-surgery nutrition monitoring makes the point plainly: there's no formal monitoring protocol for GLP-1 patients the way there is for surgical weight loss patients, despite a comparable nutritional risk profile. Protein target guidance across the literature clusters around 1.2–2.0 g/kg/day, but keep in mind, that is a huge range. For a 150lb person, that's like recommending between 82 and 136 grams of protein.


Gallbladder and pancreatic signals are real, but proportionate. A pharmacovigilance analysis and a separate review of gallbladder disease risk both confirm an elevated biliary risk, most plausibly explained by rapid weight loss reducing gallbladder motility rather than a direct drug toxicity. A 2025 analysis specifically pins the pancreatic signal on this biliary mechanism. Confirmed acute pancreatitis, once you control for confounders, is rare: a one-year UK hospital audit of tirzepatide patients found no chronic pancreatitis cases and concluded overall risk was low.


Stop the drug, and much of the benefit unwinds.

This is the part patients hear least about before starting. The STEP-1 extension trial found patients regained 11.6 percentage points of lost weight within a year of stopping semaglutide, versus 1.9 points in the placebo group, roughly two-thirds of what was lost. SURMOUNT-4 showed the same pattern for tirzepatide, with the degree of regain tracking the degree of reversal in blood pressure and cholesterol. Real-world data is somewhat more forgiving. Patients who taper rather than stop cold, or who restart or switch to another treatment, regain less than trial populations suggest, but the pattern suggests this is not a course of treatment with a finish line, unless the underlying metabolic and behavioral drivers are addressed while it's on board.


The Ugly

Compounded semaglutide has hurt people, mechanically. During the shortage years, the FDA logged adverse events tied specifically to dosing errors. Patients drawing 5 to 20 times the intended dose from multidose vials because they'd never self-injected before and nobody walked them through it. Nausea, vomiting, pancreatitis, hospitalization. This wasn't a problem with the molecule. It was a problem with handing people an unfamiliar delivery system and no training. Between the lack of education with diet and resistance training to try to avoid the bad pieces and the lack of preparedness to take it, one of my biggest concerns as a clinician is we're pushing it on TV faster than we can truly support those who are taking it, and you could get hurt.


Peptides are the real wild west. It's vague for one, but also the evidence is limited. BPC-157, TB-500, and their cousins get discussed like established therapeutics in wellness spaces, but the human evidence for BPC-157 specifically comes from roughly 30 people across three small, non-randomized pilot studies, and everything else is predominantly rodent data. The regulatory status has been genuinely confusing: the FDA classified it as a Category 2 "significant safety risk" substance in 2023, then removed it from that category in April 2026 for procedural reasons (the original nominators withdrew their objection, not because new safety data emerged). An FDA advisory panel voted 8-6 in July 2026 to recommend it for the legal compounding list, a recommendation that still requires formal rule-making before it means anything at the pharmacy counter. So the commerce of this bucket of compounds is especially concerning. If it can't be sold directly but is secured through third-party means, who is validating the safety?


So my answer to, "What are your thoughts on GLP-1?"

It depends.

For some people, it's game-changing, but it's not without risk. And when it comes to longevity, support is the name of the game. It's not biohacking, because I'll tell you why: when you shut something off or amp up one pathway for an extended period of time, something is getting suppressed that likely has purpose. If you are bringing something back into balance, that's different. So what gets turned off when GLP-1 is "turned on" for an extended period of time?


One that stands out that we can actually measure, is ghrelin. GLP-1 directly suppresses ghrelin release, and ghrelin isn't just "the hunger hormone." It drives the fasting-linked growth hormone pulse and has documented cardioprotective and anti-inflammatory effects, plus autophagy-mediated neuroprotective signaling shown in Parkinson's models. That's real protective work happening during the fasting windows GLP-1 drugs are specifically designed to erase.


Autophagy itself is the one I keep circling back to, though I want to be honest that the evidence is genuinely split. The mechanistic logic is straightforward: GLP-1 stimulates insulin, insulin activates mTOR, and mTOR is autophagy's main brake, so continuous receptor occupancy should mean a suppressed autophagy floor. But the actual data complicates that story. The caloric deficit these drugs reliably produce is one of the most robust autophagy triggers there is, and preclinical work on semaglutide has even pointed toward autophagy induction in some tissues via AMPK-dependent pathways, not suppression. Nobody has nailed this down cleanly in humans yet, which is itself the point.


We're extending receptor activation roughly 5000x past its natural half-life, and we genuinely don't know everything that trades away because of it.

My advice: Go in with eyes open!

I'll leave the body-shaming and toxicity of thinness that we've picked back up from the 90s for another day. I thought I was done with that crap, but here we are. I will say, my hope for all of us is that we can eat more vegetables and less shame.


References

  1. Yan H, et al. U.S. Eligibility and Preventable Cardiovascular, Diabetes, and Kidney Outcomes From Semaglutide in the SELECT Trial. JACC Adv. 2025. https://doi.org/10.1016/j.jacadv.2025.101773

  2. Cholesterol Treatment Trialists' Collaboration statin meta-analysis. https://pubmed.ncbi.nlm.nih.gov/23928920/

  3. Colhoun HM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024. https://doi.org/10.1038/s41591-024-03015-5

  4. Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial. Eur Heart J. 2025. https://academic.oup.com/eurheartj/article/46/12/1096/7745056

  5. Klausen MK, et al. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br J Pharmacol. 2022. https://doi.org/10.1111/bph.15677

  6. The potential role of GLP-1 receptor agonists in substance use disorders. Front Pharmacol. 2026. https://doi.org/10.3389/fphar.2025.1702448

  7. Effects of GLP-1 RAs on alcohol consumption: a systematic review and meta-analysis. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12663662/

  8. Alissou M, et al. Impact of Semaglutide on fat mass, lean mass and muscle function: The SEMALEAN study. Diabetes Obes Metab. 2025. https://doi.org/10.1111/dom.70141

  9. Greater lean-body-mass decline with tirzepatide than semaglutide in routine care. medRxiv. 2026. https://www.medrxiv.org/content/10.64898/2026.04.11.26350687v1.full

  10. Hidalgo Ramos RA, et al. Effects of Tirzepatide on Skeletal Muscle Mass in Adults: A Systematic Review. Cureus.2025. https://doi.org/10.7759/cureus.89020

  11. Micronutrient and Nutritional Deficiencies Associated With GLP-1 RA Therapy: A Narrative Review. 2026. https://pubmed.ncbi.nlm.nih.gov/41549912/

  12. Macronutrient, Micronutrient Supplementation and Monitoring for Patients on GLP-1 Agonists. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12693348/

  13. Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis. Front Pharmacol. 2025. https://doi.org/10.3389/fphar.2025.1509561

  14. GLP-1 receptor agonists and gallbladder disease risk. 2025. https://doi.org/10.1177/20420188251406456

  15. The pancreatic signal of GLP-1 receptor agonists: A biliary mechanism. 2025. https://doi.org/10.1002/bcp.70512

  16. Pancreatitis in Patients Receiving Tirzepatide (Mounjaro): A One-Year Audit. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12707267/

  17. Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review. J Clin Med. 2025. https://doi.org/10.3390/jcm14113791

  18. Weight loss maintenance after tirzepatide cessation (SURMOUNT-4 follow-up). Life Metab.https://academic.oup.com/lifemeta/article/4/5/loaf024

  19. FDA MedWatch: Dosing Errors Associated with Compounded Injectable Semaglutide Products. 2024. https://content.govdelivery.com/accounts/USFDA/bulletins/3ab6dfa

  20. BPC-157 Peptide: Facts, Risks, and FDA Status Explained. 2026. https://www.healthcareontime.com/health-tips/bpc-157-peptide-facts-risks-and-fda-status-explained/

  21. What's Changing With Peptide Regulation in 2026. BSCG. https://www.bscg.org/blogs/single/whats-changing-with-peptide-regulation-in-2026

  22. GLP-1 suppression of ghrelin (liraglutide mouse model). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755422/

  23. Ghrelin cardioprotective and anti-inflammatory signaling. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405061/

  24. Ghrelin autophagy-mediated neuroprotection in Parkinson's models. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872958/

  25. Spotlight on the Mechanism of Action of Semaglutide (autophagy/AMPK). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674233/


Comments

bottom of page